enGene Therapeutics (ENGN) Cash & Equivalents (2022 - 2026)
enGene Therapeutics' Cash & Equivalents came in at $41.03 million for fiscal Q3 2026 (quarter ended Jul 31, 2026), up 25.8% from $32.62 million a year earlier and up 37.5% from the prior quarter.
Powered by 
Analysis
enGene Therapeutics (ENGN) Cash & Equivalents (2022 - 2026) Analysis & Trends
At the end of FY2025 (ended Oct 31, 2025), enGene Therapeutics' Cash & Equivalents was $50.15 million, down 71.0% from FY2024.
- Cash & Equivalents carries a three-year compound annual growth rate of 34.9% (FY2022 to FY2025).
- Going back by fiscal year, Cash & Equivalents was $173 million in FY2024 (+112.2%), $81.52 million in FY2023 (+298.9%) and $20.43 million in FY2022.
- The five-year range for quarterly Cash & Equivalents is $20.43 million (fiscal Q4 2022) to $264.81 million (fiscal Q2 2024).
- Year-over-year, Cash & Equivalents increased in two of the last eight quarters, with an average decline of 26.9%.
- The fastest year-over-year change in Cash & Equivalents over five years came in fiscal Q4 2023 (growth of 298.9%), and the weakest in fiscal Q3 2025 (a decline of 87.3%).
- Business Quant data shows ENGN's Cash & Equivalents at $29.83 million (Q2 2026), $36.61 million (Q1 2026) and $50.15 million (Q4 2025) in the three fiscal quarters before Q3 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 976.00 Mn |
| 10 | enGene Therapeutics | 132.69 Mn | 132.69 Mn | - | 41.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | 41.03 Mn |
| Apr 30, 2026 | 29.83 Mn |
| Jan 31, 2026 | 36.61 Mn |
| Oct 31, 2025 | 50.15 Mn |
| Jul 31, 2025 | 32.62 Mn |
| Apr 30, 2025 | 57.55 Mn |
| Jan 31, 2025 | 62.35 Mn |
| Oct 31, 2024 | 173.00 Mn |
| Jul 31, 2024 | 257.68 Mn |
| Apr 30, 2024 | 264.81 Mn |
| Jan 31, 2024 | 85.65 Mn |
| Oct 31, 2023 | 81.52 Mn |
| Oct 31, 2022 | 20.43 Mn |
API Access
enGene Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ENGN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "ENGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ENGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();